Tuesday's Health Winners & Losers

Updated from 2:12 p.m. EDT

Positive study data and announcements made at the annual Digestive Disease Week conference edged health stocks slightly higher Tuesday.

Cytogen(CYTO Quote) said new results from a large cohort study on Prostastcint, which images the extent and spread of prostate cancer, are promising in predicting prognosis of the disease. Shares of the biopharmaceutical company were up 10 cents, or 4.8%, to $2.20.

Celgene(CELG Quote) was up 97 cents, or 1.5%, to $65.97, after the biopharmaceutical company said results from a Phase II study on CC-10004, an oral anti-inflammatory agent, achieved its primary endpoint. The company said it plans to advance the development of its oral anti-inflammatory candidates across a broad range of inflammatory diseases.

Also up, Auxilium Pharmaceuticals (AUXL Quote) announced data that show improvements in symptoms of decreased libido, energy levels and erectile function in 76% of men with diminished testosterone production after they switched to its Testim from Solvay SA's AndroGel. The company's shares rose 99 cents, or 6.5%, to $16.23.

Other industry names used Digestive Disease Week in Washington, D.C., as a platform to present positive study data. PDL BioPharma(PDLI Quote) said that long-term data from a follow-up of a Phase I and Phase I/II study suggested that Nuvion, a treatment it is developing for intravenous steroid-refractory ulcerative colitis, an inflammatory bowel disease that attacks the colon, produced a sustained clinical response of up to 310 days and was adequately tolerated. It is also presenting early data regarding the antibody's potential to treat Crohn's disease. The pharmaceutical company's shares were up 54 cents, or 2%, to $27.04.